Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Phosphodiesterase Inhibitors Say No to Alzheimer's Disease Publisher Pubmed



Nabavi SM1 ; Talarek S2 ; Listos J2 ; Nabavi SF1 ; Devi KP3 ; Roberto De Oliveira M4 ; Tewari D5 ; Arguelles S6 ; Mehrzadi S7 ; Hosseinzadeh A7 ; Donofrio G8 ; Orhan IE9 ; Sureda A10 ; Xu S11 Show All Authors
Authors
  1. Nabavi SM1
  2. Talarek S2
  3. Listos J2
  4. Nabavi SF1
  5. Devi KP3
  6. Roberto De Oliveira M4
  7. Tewari D5
  8. Arguelles S6
  9. Mehrzadi S7
  10. Hosseinzadeh A7
  11. Donofrio G8
  12. Orhan IE9
  13. Sureda A10
  14. Xu S11
  15. Momtaz S12, 13
  16. Farzaei MH14

Source: Food and Chemical Toxicology Published:2019


Abstract

Phosphodiesterases (PDEs) consisted of 11 subtypes (PDE1 to PDE11) and over 40 isoforms that regulate levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), the second messengers in cell functions. PDE inhibitors (PDEIs) have been attractive therapeutic targets due to their involvement in diverse medical conditions, e.g. cardiovascular diseases, autoimmune diseases, Alzheimer's disease (AD), etc. Among them; AD with a complex pathology is a progressive neurodegenerative disorder which affect mostly senile people in the world and only symptomatic treatment particularly using cholinesterase inhibitors in clinic is available at the moment for AD. Consequently, novel treatment strategies towards AD are still searched extensively. Since PDEs are broadly expressed in the brain, PDEIs are considered to modulate neurodegenerative conditions through regulating cAMP and cGMP in the brain. In this sense, several synthetic or natural molecules inhibiting various PDE subtypes such as rolipram and roflumilast (PDE4 inhibitors), vinpocetine (PDE1 inhibitor), cilostazol and milrinone (PDE3 inhibitors), sildenafil and tadalafil (PDE5 inhibitors), etc have been reported showing encouraging results for the treatment of AD. In this review, PDE superfamily will be scrutinized from the view point of structural features, isoforms, functions and pharmacology particularly attributed to PDEs as target for AD therapy. © 2019 Elsevier Ltd
Related Docs
View other Related Docs
1. How Do Phosphodiesterase-5 Inhibitors Affect Cancer? a Focus on Glioblastoma Multiforme, Pharmacological Reports (2022)
2. Phosphodiesterase 4 and 7 Inhibitors Produce Protective Effects Against High Glucose-Induced Neurotoxicity in Pc12 Cells Via Modulation of the Oxidative Stress, Apoptosis and Inflammation Pathways, Metabolic Brain Disease (2018)
3. Cilostazol Pretreatment Prevents Ptsd-Related Anxiety Behavior Through Reduction of Hippocampal Neuroinflammation, Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
Experts (# of related papers)
View all Related Experts
Mohammad Mahdavi (8)
Tahmineh Akbarzadeh (4)
Other Related Docs
4. Rolipram and Pentoxifylline Combination Ameliorates Experimental Diabetic Neuropathy Through Inhibition of Oxidative Stress and Inflammatory Pathways in the Dorsal Root Ganglion Neurons, Metabolic Brain Disease (2022)
5. Sildenafil Beyond Erectile Dysfunction and Pulmonary Arterial Hypertension: Thinking About New Indications, Fundamental and Clinical Pharmacology (2021)
6. The Role of Creb and Bdnf in Neurobiology and Treatment of Alzheimer's Disease, Life Sciences (2020)
7. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)
8. Dual Functional Cholinesterase and Carbonic Anhydrase Inhibitors for the Treatment of Alzheimer's Disease: Design, Synthesis, in Vitro, and in Silico Evaluations of Coumarin-Dihydropyridine Derivatives, Journal of Molecular Structure (2023)
9. New Imidazo[1,2-A]Pyridin-2-Yl Derivatives As Ache, Bche, and Lox Inhibitors; Design, Synthesis, and Biological Evaluation, Letters in Drug Design and Discovery (2023)
10. Synthesis and Evaluation of Novel Arylisoxazoles Linked to Tacrine Moiety: In Vitro and in Vivo Biological Activities Against Alzheimer’S Disease, Molecular Diversity (2022)
11. Thieno[2,3-B]Pyridine Amines: Synthesis and Evaluation of Tacrine Analogs Against Biological Activities Related to Alzheimer's Disease, Archiv der Pharmazie (2020)
12. A Review on Flavonoid-Based Scaffolds As Multi-Target-Directed Ligands (Mtdls) for Alzheimer's Disease, European Journal of Medicinal Chemistry (2018)
13. Protective Effects of Flavonoids Against Alzheimer's Disease-Related Neural Dysfunctions, Biomedicine and Pharmacotherapy (2017)
14. Design, Synthesis, and Biological Evaluation of Selective and Potent Carbazole-Based Butyrylcholinesterase Inhibitors, Bioorganic and Medicinal Chemistry (2018)
15. Paradoxical Role of Pka Inhibitor on Amyloidβ-Induced Memory Deficit, Physiology and Behavior (2015)
16. Toll-Like Receptors in Alzheimer's Disease, Journal of Neuroimmunology (2020)
17. Synthesis and Biological Activity of Some Benzochromenoquinolinones: Tacrine Analogs As Potent Anti-Alzheimer's Agents, Chemistry and Biodiversity (2019)
18. Amino-7,8-Dihydro-4H-Chromenone Derivatives As Potential Inhibitors of Acetylcholinesterase and Butyrylcholinesterase for Alzheimer’S Disease Management; in Vitro and in Silico Study, BMC Chemistry (2024)
19. Anticholinesterase Activities of Novel Isoindolin-1,3-Dione-Based Acetohydrazide Derivatives: Design, Synthesis, Biological Evaluation, Molecular Dynamic Study, BMC Chemistry (2024)
20. Combination Therapy in Alzheimer's Disease: Is It Time?, Journal of Alzheimer's Disease (2022)